Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5.2%

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) shot up 5.2% on Monday . The stock traded as high as $16.03 and last traded at $15.70. 267,345 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 837,835 shares. The stock had previously closed at $14.92.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DAWN. Oppenheimer restated a "market perform" rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Needham & Company LLC upped their target price on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Tuesday, February 27th. Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $39.33.

Day One Biopharmaceuticals Price Performance

The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.87 and a beta of -1.48. The firm's fifty day moving average is $15.22 and its 200-day moving average is $13.84.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the sale, the general counsel now directly owns 16,585 shares of the company's stock, valued at $252,921.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the sale, the insider now directly owns 1,224,662 shares of the company's stock, valued at $19,729,304.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 3,242 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the sale, the general counsel now directly owns 16,585 shares in the company, valued at approximately $252,921.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,781 shares of company stock valued at $883,160. Company insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock worth $27,000 after acquiring an additional 1,262 shares during the period. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth about $29,000. Quintet Private Bank Europe S.A. increased its holdings in shares of Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after acquiring an additional 1,000 shares during the period. Amalgamated Bank increased its holdings in shares of Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company's stock worth $106,000 after acquiring an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company's stock worth $147,000 after acquiring an additional 2,554 shares during the period. Institutional investors and hedge funds own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.